Dimenydrinate vs Ondansetron for PONV (DONV)

Comparison of the Effectiveness of Dimenydrinate vs Ondasetron on the Prevention of Postoperative Nausea and Vomiting

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05590936

Acronym

DONV

Enrollment

190

Registered

2022-10-21

Start date

2018-01-01

Completion date

2022-12-07

Last updated

2022-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PONV in Laparoscopic Cholocystectomies

Brief summary

This study will investigate the impact of dimenydrinate (H1-receptor antagonist) versus ondansetron (HT3-receptor antagonist) in postoperative nausea and vomiting, in surgery-related preoperative stress and in the incidence of postoperative complications that could lengthen the LOS in PACU and/or the overall LOS.

Detailed description

Dimenydrinate has been extensively used for motion sickness. However, as far as postoperative nausea and vomiting is concerned the results are still conflicting. This study will investigate the impact of dimenydrinate (H1-receptor antagonist) versus ondansetron (HT3-receptor antagonist) in postoperative nausea and vomiting, in surgery-related preoperative stress and in the incidence of postoperative complications that could lengthen the LOS in PACU and/or the overall LOS.

Interventions

DRUGDimenhydrinate Tablets

2 hours preoperative per os administration of 50 mg dimenhydrinate

DRUGOndansetron iv

Intraoperative intravenous administration of 4 mg ondansetron

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Age 18-75 years old * ASA PS I-III * Undergoing laparoscopic general surgery operations or laparoscopic gynecological operations

Exclusion criteria

* Refused to participate * Age other than 18-75 years old * Pregnant patients * Non-elective operations * Patients that are not able to receive p.os agents * Medical history of Brugada Sdr or Brugada-like/related ECG abnormalities * Long-Qt Sdr or concurrent use of medications that may cause long-QT ECG abnormalities * Medical or family history of psychosis * Allergy in dimenydrinate or in dimenydrinate drug versions * Perioperative use of dexamethasone

Design outcomes

Primary

Measure	Time frame	Description
PONV	30 minutes postoperative	PONV recording in patients undergone laparoscopic cholocystectomy

Secondary

Measure	Time frame	Description
preoperative anxiety	24 hours before operation	preoperative anxiety recording in patients undergone laparoscopic cholocystectomy measured by one hundred points scale
Awaken time	on extubation	time from anesthetic drug cessation until extubation

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026